Abstract
The myelodysplastic syndromes (MDS) are a group of disorders characterized by dysplastic hemopoiesis and an increased risk of leukemic transformation. The process of angiogenesis has been implicated in the pathogenesis and evolution of MDS. In this study the proliferative activity and extent of angiogenesis was examined in bone marrow samples from 54 patients with MDS in relation to clinicopathologic features. Cellular proliferation and microvascular density (MVD) were examined immunohistochemically, using the monoclonal antibody MIB-1 (Ki-67) and an anti-CD34 monoclonal antibody respectively. Serum concentrations of interleukin-6 (IL-6) were measured by ELISA. The results showed that the MIB-1 Labeling Index (MIB-1 LI), MVD and IL-6 increased significantly with advancing severity of disease. Among the MDS-FAB subtypes, MIB-1 LI, MVD and IL-6 were significantly higher in RAEB-t, RAEB and CMML in comparison to RA and RARS (p < 0.0001 in all cases). Similarly, MIB-1 and MVD were increased in patients with score 3 in comparison to scores 0 and 1 in the IPSS system (p < 0.05). All parameters studied were significantly higher in patients versus controls. We conclude that cellular proliferative activity and angiogenesis are associated with disease progression in MDS patients.
Similar content being viewed by others
References
A Aguayo H Kantarjian T Manshouri C Gidel E Estey D Thomas C Koller Z Estrov S O’Brien M Keating E Freireich M Albitar (2000) ArticleTitleAngiogenesis in acute and chronic leukemias and myelodysplastic syndromes Blood 96 2240–2245
M Albitar (2001) ArticleTitleAngiogenesis in acute myeloid leukemia and myelodysplastic syndrome Acta Haematol 106 170–176
M Alexandrakis S Coulocheri I Xylouri E Ganotakis P Eliakis N Karkavitsas G Eliopoulos (1998) ArticleTitleElevated serum TNF-alpha concentrations are predictive of shortened survival in patients with high-risk myelodysplastic syndromes Haematologia (Budap) 29 13–24
C Aul A Giagounidis U Germing A Ganser (2002) ArticleTitleEvaluating the prognosis of patients with myelodysplastic syndromes Am J Hematol 81 485–497
J Bennett D Catovsky M Daniel G Flandrin D Galton H Gralnick C. Sultan (1982) ArticleTitleProposals for the classification of the myelodysplastic syndromes Br J Haematol 51 189–199
J Bennett D Catovsky M Daniel G Flandrin D Galton H Gralnick C Sultan C Cox (1994) ArticleTitleThe chronic myeloid leukaemias: guidelines for distinguishing chronic granulocytic, atypical chronic myeloid, and chronic myelomonocytic leukaemia Br J Haematol 87 746–754
J Bennett (2000) ArticleTitleThe World Health Organization (WHO) classification of acute leukemias and the myelodysplastic syndromes Int J Hematol 72 131–133
C Belli S Acevedo R Bengio G Arrossagaray N Watman N Rolssi J Garcia G Flore S Goldztein I Larripa (2002) ArticleTitleDetection of risk groups in myelodysplastic syndromes. A multicenter study. Haematologica 87 9–16
D Brown K Gatter (1990) ArticleTitleMonoclonal antibody Ki-67: its use in histopathology Histopathology 17 489–503
B Dankbar T Padro R Leo B Feldmann M Kropff R Mesters H Serve W Berdel J Kienast (2000) ArticleTitleVascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma Blood 95 2630–2636
F Di Raimondo GA Palumbo S Molica R Giustolisi (2001) ArticleTitleAngiogenesis in chronic myeloproliferative diseases Acta Haematol 106 177–183
W Fiedler E Suciu C Wittlief W Ostertag D Hossfeld (1990) ArticleTitleMechanisms of growth factor expression in acute myeloid leukemia (AML) Leukemia 4 459–461
J Gerdes H Lemke H Baisch H Wacker U Schwab H Stein (1984) ArticleTitleCell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67 J Immunol. 133 1710–1715
P Greenberg C Cox MM Le Beau P Fenaux P Morel G Sanz M Sanz T Vallespi T Hamblin D Oscier K Ohyashiki K Toyama C Aul G Muft J Bennett (1997) ArticleTitleInternational scoring system for evaluating prognosis in myelodysplastic syndromes Blood 89 2079–2088
M Herold F Schmalzl H Zwierzina (1992) ArticleTitleIncreased serum interleukin 6 levels in patients with myelodysplastic syndromes Leuk Res 16 585–588
P Kanavaros K Stefanaki D Rontogianni K Darivianaki M Vlychou E Papadaki G Eliopoulos M Bakiri C Matsouka S Kakolyris V Georgoulias (1999) ArticleTitleImmunohistochemical detection of p53, mdm2, waf1/p21, and Ki67 proteins in bone marrow biopsies in myelodysplastic syndroms, acute myelogenous leukaemias and chronic myeloproliferative disorders Clin Exp Pathol 47 231–238
P Korkolopoulou E Apostolidou P Pavlopoulos N Kavantzas N Vyniou I Thymara E Terpos E Patsouris X Yataganas P Davaris (2001) ArticleTitlePrognostic evaluation of the microvascular network in myelodysplastic syndromes Leukemia 15 1369–1376
M Kubbutat G Key M Duchrow C Schluter H Flad J Gerdes (1994) ArticleTitleEpitope analysis of antibodies recognising the cell proliferation associated nuclear antigen previously defined by the antibody Ki-67 (Ki-67 protein) J Clin Pathol 47 524–528
A Leary K Ikebuchi Y Hirai G Wong Y Yang S Clark M Ogawa (1988) ArticleTitleSynergism between interleukin-6 and interleukin-3 in supporting proliferation of human hematopoietic stem cells: comparison with interleukin-1 alpha Blood 71 1759–1763
T Moehler K Neben A Ho H Goldschmidt (2001) ArticleTitleAngiogenesis in hematologic malignancies Ann Hematol 80 695–705
C Musolino L Calabro G Bellomo F Martello B Loteta C pezzano V Rizzo A Alonci (2000) ArticleTitleSoluble angiogenic factors: implications for chronic myeloproliferative disorders Am J Hematol 69 159–163
T Nosslinger R Reisner E Koller H Gruner H Tuchler H Nowotny E Pittermann M Pfeilstocker (2000) ArticleTitleMyelodysplastic syndromes, from the French-American-British to World Health Organization: comparison of classifications on 431 unselected patients from a single institution Blood 98 2935–2941
T Ota M Hino T Yamane K Ota A Mugitani K Park T Im T Takubo N Tatsumi (1998) ArticleTitleInterleukin-6 may play an important role in thrombopoiesis: a case of leukemic transformation from myelodysplastic syndrome Ann Hematol 77 243–244
T Padro S Ruiz R Bieker H Burger M Steins J Kienast T Buchner W Berdel R Mesters (2000) ArticleTitleIncreased angiogenesis in the bone marrow of patients with acute myeloid leukemia Blood 95 2637–2644
K Panteli N Zagorianakou M Bai A Katsaraki NJ Agnantis K Bourantas (2004) ArticleTitleAngiogenesis in chronic myeloproliferative diseases detected by CD34 expression Eur J Haematol 72 410–415
J Parker G Mufti F Rasool A Mijovic S Devereux A Pagliuca (2000) ArticleTitleThe role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS Blood 96 3932–3938
W Pellegrini F Facchetti D Marocolo L Salvi A Capucci A Tironi G Rossi (1995) ArticleTitleAssessment of cell proliferation in normal and pathological bone marrow biopsies: a study using double sequential immunophenotyping on paraffin sections Histopathology 27 397–405
A Perez-Atayde S Sallan U Tedrow S Connors E Allred J Folkman (1997) ArticleTitleSpectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia Am J Pathol 150 815–821
G Pruneri F Bertolini D Soligo N Carboni A Cortelezzi P Ferrucci R Buffa G Lambertenghi-Deliliers F Pezzella (1999) ArticleTitleAngiogenesis in myelodysplastic syndromes Br J Cancer 81 1398–1401
A Raza S Gezer S Mundle X Gao S Alvi R Borok S Rifkin A Iftikhar V Shetty A Parcharidou J Loew B Marcus Z Khan C Chaney J Showel S Gregory H Preisler (1995) ArticleTitleApoptosis in bone marrow biopsy samples involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes Blood 86 268–276
K Shimazaki K Ohshima J Suzumiya C Kawasaki M Kikuchi (2000) ArticleTitleEvaluation of apoptosis as a prognostic factor in myelodysplastic syndromes Br J Haematol 110 584–590
D White A Smith J Smith (1994) ArticleTitleAssessment of proliferative activity in leukaemic bone marrow using the monoclonal antibody Ki-67 J Clin Pathol 47 209–213
R Willemze W Fibbe J Falkenburg J Kluin-Nelemans P Kluin J Landegent (1993) ArticleTitleBiology and treatment of myelodysplastic syndromes-developments in the past decade Ann Hematol 66 107–115
F Yi B Wang X Liu (1993) ArticleTitleThe significance of Ki-67, BrdU and OKT9 expression in determination of myelodysplastic syndromes by use of APAAP technique J Tongji Med Univ 13 30–33
F Zorat V Shetty D Dutt L Lisak F Nascimben K Allampallam S Dar A York S Gezer P Venugopal A Raza (2001) ArticleTitleThe clinical and biological effects of thalidomide in patients with myelodysplastic syndromes Br J Haematol 115 881–894
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Alexandrakis, M.G., Passam, F.H., Kyriakou, D.S. et al. Expression of the proliferation-associated nuclear protein MIB-1 and its relationship with microvascular density in bone marrow biopsies of patients with myelodysplastic syndromes. J Mol Hist 35, 857–863 (2004). https://doi.org/10.1007/s10735-004-2341-0
Issue Date:
DOI: https://doi.org/10.1007/s10735-004-2341-0